Abbott to close $21B Exact Sciences deal
Abbott Laboratories is set to close its $21 billion acquisition of Exact Sciences, a major horizontal move that expands Abbott’s cancer diagnostics footprint. The transaction highlights ongoing consolidation in diagnostics and will reshape competitive positioning in high-margin testing markets. (modernhealthcare.com)
Abbott announced the transaction is expected to close on Monday, March 23, 2026. (abbott.mediaroom.com) The merger consideration is $105.00 in cash per Exact Sciences share, implying roughly $21 billion in equity value and an estimated $23 billion enterprise value after accounting for Exact’s debt. (abbott.mediaroom.com) Exact’s commercial and clinical portfolio being acquired includes the Cologuard and Cologuard Plus stool-DNA colorectal tests, the Oncotype DX genomic testing franchise, and the Cancerguard multi-cancer early-detection blood test. ( ) Abbott completed a roughly $20 billion senior notes offering to help finance the acquisition, and the company has said it will combine cash on hand with debt financing to fund the deal. (massdevice.com) Abbott disclosed an expected run-rate synergy target of about $100 million annually, while filings show Exact carried roughly $1.8 billion of net debt that factors into the enterprise valuation. ( ) Exact stockholders voted to approve the merger at a special meeting on February 20, 2026, and Abbott said all regulatory clearances required for closing have been received; the merger agreement includes a $628.7 million termination fee and an outside completion date of November 19, 2026. ( )
